HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hayashida, N. Articles by Aoyagi, S. Search for Related Content PubMed PubMed Citation Articles by Hayashida, N. Articles by Aoyagi, S.

Ann Thorac Surg 1999;68:1661-1667
© 1999 The Society of Thoracic Surgeons

---

Original Articles

Inhibitory effect of milrinone on cytokine production after cardiopulmonary bypass

^a Department of Surgery, Kurume University, Fukuoka, Japan

Address reprint requests to Dr Hayashida, Department of Surgery, Kurume University, 67 Asahi-machi, Kurume, Fukuoka, 830-0011 Japan

Background. It has been suggested that cyclic adenosine monophosphate-elevating agents suppress cytokine production. To evaluate the effects of milrinone, a phosphodiesterase III inhibitor, on cytokine production after cardiopulmonary bypass, we conducted a prospective randomized study.

Methods. Twenty-four patients undergoing coronary artery bypass grafting were randomized to receive either milrinone treatment (milrinone, n = 12) or no milrinone treatment (control, n = 12). Administration of milrinone (0.5 µg · kg^-1 · min^-1) was started after induction of anesthesia and was continued for 24 hours. Blood samples for determination of plasma cyclic adenosine monophosphate, tumor necrosis factor-, interleukin-1ß, interleukin-6, and interleukin-8 levels were collected perioperatively.

Results. No significant differences were observed in tumor necrosis factor- and interleukin-8 levels between the groups. Interleukin-1ß and interleukin-6 levels after cardiopulmonary bypass were significantly (p < 0.05) lower in the milrinone group than in the control group. Plasma levels of cyclic adenosine monophosphate increased significantly (p < 0.05) after the administration of milrinone and the levels correlated inversely (r = -0.55, p < 0.01) with interleukin-6 levels.

Conclusions. The results indicate that milrinone suppresses cytokine production by elevating cyclic adenosine monophosphate levels in patients undergoing cardiopulmonary bypass. With its positive inotropic and vasodilator activities, milrinone may have antiinflammatory effects.

This article has been cited by other articles:

				A. Y. Denault, Y. Lamarche, P. Couture, F. Haddad, J. Lambert, J.-C. Tardif, and L. P. Perrault Inhaled milrinone: a new alternative in cardiac surgery? Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2006; 10(4): 346 - 360. [Abstract] [PDF]

				A. Boning, J. Scheewe, T. Ivers, C. Friedrich, J. Stieh, S. Freitag, and J. T. Cremer Phosphorylcholine or heparin coating for pediatric extracorporeal circulation causes similar biologic effects in neonates and infants J. Thorac. Cardiovasc. Surg., May 1, 2004; 127(5): 1458 - 1465. [Abstract] [Full Text] [PDF]

				A. J. Chong, C. R. Hampton, and E. D. Verrier Microvascular Inflammatory Response in Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2003; 7(3): 333 - 354. [Abstract] [PDF]

				N. Hayashida, S. Chihara, E. Tayama, T. Takaseya, N. Enomoto, T. Kawara, and S. Aoyagi Antiinflammatory effects of colforsin daropate hydrochloride, a novel water-soluble forskolin derivative Ann. Thorac. Surg., June 1, 2001; 71(6): 1931 - 1938. [Abstract] [Full Text] [PDF]

				N. Hayashida, S. Chihara, H. Kashikie, E. Tayama, S. Yokose, K. Akasu, and S. Aoyagi Effects of intraoperative administration of atrial natriuretic peptide Ann. Thorac. Surg., October 1, 2000; 70(4): 1319 - 1326. [Abstract] [Full Text] [PDF]